LD-2 disclosure · 3rd Quarter - Report
BLUEBIRD BIO
Client
- Name
- BLUEBIRD BIO
- Description
- Clinical-stage company developing gene therapies for severe genetic and rare diseases.
- Location
- District of Columbia · United States of America
Registrant
- Description
- Consulting firm.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
4 issuesHealth Issues
Monitored issues related to FDA approval of breakthrough therapies. Cures 2.0 and issues related to FDA.
LobbyistsMARY BETH SAVARY TAYLOR · GREG D'ANGELO
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS)
Budget/Appropriations
Monitored S.Con.Res. 14, FY 2022 Budget Resolution.
LobbyistsMARY BETH SAVARY TAYLOR · GREG D'ANGELO
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS)
Medicare/Medicaid
Issues related to value based payment and ensuring access to gene therapies. Issues related to rulemaking supporting value based payment arrangements. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 5376, the Build Back Better Act, as it relates to drug pricing.
LobbyistsMARY BETH SAVARY TAYLOR · GREG D'ANGELO